Neurotherapeutics Role of Neuroinflammation in Parkinson's Disease and Related Disorders Modeling and Mechanistic Investigation of α-synucl
Neurotherapeutics Role of Neuroinflammation in Parkinson's Disease and Related Disorders Modeling and Mechanistic Investigation of α-synuclein aggregation. 18(3):1692-1709
Subject Terms:
Medical and Health Sciences, Basic Medicine, Neurosciences, Medicin och hälsovetenskap, Medicinska och farmaceutiska grundvetenskaper, Neur
Aggregation of α-synuclein is associated with neurodegeneration and a hallmark pathology in synucleinopathies. These aggregates are thought
Aggregation of α-synuclein is associated with neurodegeneration and a hallmark pathology in synucleinopathies. These aggregates are thought to function as prion-like particles where the conformation of misfolded α-synuclein determines the traits of the induced pathology, similar to prion diseases. Still, little is known about the molecular targets facilitating the conformation-specific biological effects, but their identification could form the basis for new therapeutic interventions. High-throughput screening of annotated compound libraries could facilitate mechanistic investigation by identifying targets with impact on α-synuclein aggregation. To this end, we developed a FRET-based cellular reporter in HEK293T cells, with sensitivity down to 6.5 nM α-synuclein seeds. Using this model system, we identified GF109203X, SB202190, and SB203580 as inhibitors capable of preventing induction of α-synuclein aggregation via inhibition of p38 MAPK and PKC, respectively. We further investigated the mechanisms underlying the protective effects and found alterations in the endo-lysosomal system to be likely candidates of the protection. We found the changes did not stem from a reduction in uptake but rather alteration of lysosomal abundance and degradative capacity. Our findings highlight the value high-throughput screening brings to the mechanistic investigation of α-synuclein aggregation while simultaneously identifying novel therapeutic compounds.
Lund University, Faculty of Medicine, Department of Experimental Medical Science, Neural Plasticity and Repair, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Neural plasticitet och reparation, Originator, Lund University, Profile areas and other strong research environments, Strategic research areas (SRA), MultiPark: Multidisciplinary research focused on Parkinson´s disease, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Strategiska forskningsområden (SFO), MultiPark: Multidisciplinary research focused on Parkinson´s disease, Originator, Lund University, Profile areas and other strong research environments, Strategic research areas (SRA), NanoLund: Centre for Nanoscience, Lunds universitet, Profilområden och andra starka forskningsmiljöer, Strategiska forskningsområden (SFO), NanoLund: Centre for Nanoscience, Originator, Lund University, Faculty of Medicine, Department of Experimental Medical Science, Chemical Biology and Therapeutics, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Kemisk biologi med inriktning mot läkemedelsutveckling, Originator, Lund University, Faculty of Medicine, Department of Experimental Medical Science, Experimental Dementia Research, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Experimentell demensforskning, Originator, Lund University, Faculty of Science, Department of Chemistry, Centre for Analysis and Synthesis, Lunds universitet, Naturvetenskapliga fakulteten, Kemiska institutionen, Centrum för analys och syntes, Originator, Lund University, Faculty of Medicine, Department of Experimental Medical Science, Molecular Neuromodulation, Lunds universitet, Medicinska fakulteten, Institutionen för experimentell medicinsk vetenskap, Molekylär neuromodulering, Originator